Laser Photocoagulation-is a treatment for wet macular degeneration. In this procedure a laser is used to destroy or to seal off newly developing blood vessels. This prevents the leakage of blood and fluid. This procedure is no longer …
Othera Pharmaceuticals, Inc., a specialty pharmaceutical company focused on treatments for ophthalmic diseases, has announced positive interim data results from its Phase 2 trial of OT-551 in treating geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD) for which there is no FDA-approved treatment.
Lucentis is currently approved by the FDA for the treatment of neovascular (wet) age-related macular degeneration (AMD) and is the only FDA-approved treatment for wet AMD proven to improve or maintain vision. Share and Enjoy: …
Laser Photocoagulation-is a treatment for wet macular degeneration. In this procedure a laser is used to destroy or to seal off newly developing blood vessels. This prevents the leakage of blood and fluid. This procedure is no longer …
Lucentis is the only FDA-approved treatment for neovascular (wet) age-related macular degeneration (ARMD), a degenerative condition of the central retina, and is the most common cause of vision loss in U.S. citizens 50 and up. …
